Cite
HARVARD Citation
Nishida, S. et al. (2022). Cellular and Humoral Immune Responses Induced by an HLA Class I–restricted Peptide Cancer Vaccine Targeting WT1 Are Associated With Favorable Clinical Outcomes in Advanced Ovarian Cancer. Journal of immunotherapy. 45 (1), p. . [Online].